What if I told you there’s a way to pull consistent income from the market… WITHOUT buying a single stock or crypto?

What if this “underground” method bypasses everything you thought you knew about trading…
And allows everyday people to quietly collect cash payouts, week after week?

It sounds almost too strange to be true. But I promise, it’s very real.

And it’s so simple, it could take just 30 minutes a day to do.

All the details are revealed in this special video:

The Little-Known Trading Blueprint That Can Turn 30 Minutes a Day Into an Extra Income Stream

Please click here to watch it now

If you’ve been looking for something outside the norm…

Something that doesn’t depend on risky bets or “buying, holding and praying”…

Then please click here and watch the video now before it gets pulled down

---

More Reading from MarketBeat Media

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Reported by Leo Miller. Originally Published: 12/16/2025. 

Quick Look

• Stryker, Amgen, and Eli Lilly have all raised their dividends, signaling increased capital returns to shareholders despite varied stock performance in 2025.
• Amgen now offers an industry-leading 3.2% dividend yield, one of the few large-cap healthcare stocks with a yield above 3%.
• Wall Street maintains a positive outlook across all three names, with Stryker offering the highest implied upside at over 20%, followed by Eli Lilly and Amgen.

Major players in healthcare are increasing their commitments to return capital to shareholders, which has led to meaningful dividend increases. Recent announcements from several large companies in the sector highlight evolving capital-return strategies, and analyst forecasts provide context for where these stocks may go next.

SYK Lifts Dividend as Analysts Eye Substantial Upside

First up is Stryker (NYSE: SYK). With a market capitalization near $135 billion, Stryker is one of the largest names in the healthcare equipment and supplies industry. Despite steady revenue growth and margins, the stock has underperformed in 2025, delivering a total return of roughly -1%. The company, however, beat estimates in its latest earningsand raised full-year guidance.

A pre-IPO Play on the Starlink Hype for Under $100? (Ad)

Elon Musk’s Starlink project is generating major speculation ahead of a potential IPO that some analysts believe could reach a historic $100 billion valuation. According to James Altucher, there may be a smart “backdoor” way for everyday investors to position ahead of that event without needing traditional IPO access — and he says it can be done for under $100. He’s also sharing a free ticker tied to this trend for anyone who wants to take a closer look.Click here to learn more

On Dec. 11, Stryker announced a 4.8% dividend increase. Its quarterly dividend will rise to $0.88 per share, payable on Jan. 30, 2026, to shareholders of record at the close of business on Dec. 31. The stock now has an indicated dividend yield of about 1%.

Wall Street analysts are fairly bullish on Stryker. The MarketBeat consensus price target of just under $432 implies roughly 22% upside. Price targets updated after the company’s Oct. 30 earnings are slightly less bullish but still indicate solid upside, averaging around $425 (about 20% upside).

AMGN Raises Outlook, Dividend Yield Eclipses 3%

Amgen (NASDAQ: AMGN) is a major player in biotechnology and pharmaceuticals, with a market capitalization near $171 billion. The stock has performed well in 2025, returning about 26% year-to-date. In its Nov. 4 results, Amgen beat estimates and raised full-year guidance. Notably, 16 of its drugs posted double-digit growth, and its largest product, Prolia, grew 9%.

On Dec. 9, Amgen declared a quarterly dividend of $2.52, a 5.9% increase. The dividend is payable on March 6, 2026, to stockholders of record at the close of business on Feb. 13, 2026. The stock now yields about 3.1%.

The MarketBeat consensus price target near $332 implies roughly 5% upside. Price targets updated after the company’s latest earnings are more optimistic, averaging about $348 and suggesting around 10% upside potential.

LLY Provides 15% Dividend Increase with Shares Up Big in 2025

Finally, Eli Lilly and Company (NYSE: LLY) is the largest healthcare company by market cap, at about $920 billion. (For comparison, Johnson & Johnson sits around $510 billion.) Lilly has delivered a strong 2025 performance, with a total return near 34%, driven largely by robust demand for its weight-loss and diabetes medicines and a healthy pipeline. In its most recent quarter, Lilly significantly beat analyst estimates on sales and adjusted EPS.

On Dec. 9, Lilly declared a quarterly dividend of $1.73, a 15.3% increase from the prior payout. The dividend is payable on March 10, 2026, to shareholders of record at the close of business on Feb. 13, 2026. Lilly’s indicated dividend yield is now nearly 0.6%.

The MarketBeat consensus price target for Lilly is near $1,109, implying about 8% upside. Targets updated after the Oct. 30 earnings report are more bullish, averaging roughly $1,138 and suggesting about 11% upside.

Among SYK, AMGN, and LLY, Amgen Leads on Income Potential

All three companies — SYK, AMGN and LLY — are important holdings in the healthcare sector and offer different mixes of growth and income. For investors prioritizing dividend income, Amgen stands out as one of the few large-cap U.S. healthcare stocks with a yield above 3%.

Thank you for subscribing to The Early Bird, MarketBeat’s 7:00 AM newsletter that covers stories that will impact the stock market each day.

This email message is a sponsored email for Reliable Trading Circle, a third-party advertiser of The Early Bird and MarketBeat. 

If you have questions or concerns about your account, don’t hesitate to contact our South Dakota based support team at contact@marketbeat.com.

If you no longer wish to receive email from The Early Bird, you can unsubscribe.

© 2006-2025 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Suite 620, Sioux Falls, S.D. 57103. USA..

Read More: 5 Best Stocks Under $5 to Buy Now (Click to Opt-In)